These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 29574484)

  • 1. The effect of solifenacin on postvoid dribbling in women: results of a randomized, double-blind placebo-controlled trial.
    Ablove T; Bell LN; Liang H; Chappell RJ; Toklu HZ; Yale SH
    Int Urogynecol J; 2018 Jul; 29(7):1051-1060. PubMed ID: 29574484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms.
    Serels SR; Toglia MR; Forero-Schwanhaeuser S; He W
    Curr Med Res Opin; 2010 Oct; 26(10):2277-85. PubMed ID: 20707767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
    Abrams P; Kelleher C; Staskin D; Rechberger T; Kay R; Martina R; Newgreen D; Paireddy A; van Maanen R; Ridder A
    Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severity of overactive bladder symptoms and response to dose escalation in a randomized, double-blind trial of solifenacin (SUNRISE).
    Cardozo L; Amarenco G; Pushkar D; Mikulas J; Drogendijk T; Wright M; Compion G;
    BJU Int; 2013 May; 111(5):804-10. PubMed ID: 23294801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial.
    Cardozo L; Hessdörfer E; Milani R; Arañó P; Dewilde L; Slack M; Drogendijk T; Wright M; Bolodeoku J;
    BJU Int; 2008 Nov; 102(9):1120-7. PubMed ID: 18990175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Efficacy and Safety of OnabotulinumtoxinA or Solifenacin Compared with Placebo in Solifenacin Naïve Patients with Refractory Overactive Bladder: Results from a Multicenter, Randomized, Double-Blind Phase 3b Trial.
    Herschorn S; Kohan A; Aliotta P; McCammon K; Sriram R; Abrams S; Lam W; Everaert K
    J Urol; 2017 Jul; 198(1):167-175. PubMed ID: 28161352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder.
    Yamaguchi O; Marui E; Kakizaki H; Itoh N; Yokota T; Okada H; Ishizuka O; Ozono S; Gotoh M; Sugiyama T; Seki N; Yoshida M;
    BJU Int; 2007 Sep; 100(3):579-87. PubMed ID: 17669143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial.
    Karram MM; Toglia MR; Serels SR; Andoh M; Fakhoury A; Forero-Schwanhaeuser S
    Urology; 2009 Jan; 73(1):14-8. PubMed ID: 18995887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.
    Wagg A; Wyndaele JJ; Sieber P
    Am J Geriatr Pharmacother; 2006 Mar; 4(1):14-24. PubMed ID: 16730617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson's disease.
    Zesiewicz TA; Evatt M; Vaughan CP; Jahan I; Singer C; Ordorica R; Salemi JL; Shaw JD; Sullivan KL;
    Parkinsonism Relat Disord; 2015 May; 21(5):514-20. PubMed ID: 25814050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Solifenacin in Children and Adolescents with Overactive Bladder: Results of a Phase 3 Randomised Clinical Trial.
    Newgreen D; Bosman B; Hollestein-Havelaar A; Dahler E; Besuyen R; Sawyer W; Bolduc S; Rittig S
    Eur Urol; 2017 Mar; 71(3):483-490. PubMed ID: 27687820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Solifenacin for overactive bladder: secondary analysis of data from VENUS based on baseline continence status.
    Toglia MR; Ostergard DR; Appell RA; Andoh M; Fakhoury A; Hussain IF
    Int Urogynecol J; 2010 Jul; 21(7):847-54. PubMed ID: 20339833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Solifenacin for overactive bladder: patient-reported outcomes from a large placebo-controlled trial.
    Toglia MR; Serels SR; Laramée C; Karram MM; Nandy IM; Andoh M; Seifeldin R; Forero-Schwanhaeuser S
    Postgrad Med; 2009 Sep; 121(5):151-8. PubMed ID: 19820284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and safety of solifenacin in patients with overactive bladder syndrome.
    Oresković S; But I; Banović M; Goldstajn MS
    Coll Antropol; 2012 Mar; 36(1):243-8. PubMed ID: 22816227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency.
    Kaplan SA; McCammon K; Fincher R; Fakhoury A; He W
    J Urol; 2009 Dec; 182(6):2825-30. PubMed ID: 19837435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and tolerability of solifenacin add-on therapy to α-blocker treated men with residual urgency and frequency.
    Kaplan SA; McCammon K; Fincher R; Fakhoury A; He W
    J Urol; 2013 Jan; 189(1 Suppl):S129-34. PubMed ID: 23234618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Solifenacin and tolterodine are equally effective in the treatment of overactive bladder symptoms.
    Ho CH; Chang TC; Lin HH; Liu SP; Huang KH; Yu HJ
    J Formos Med Assoc; 2010 Oct; 109(10):702-8. PubMed ID: 20970066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A placebo-controlled, double-blind, randomized trial of single daily dose of anti-muscarinic drug solifenacin succinate in patients with overactive bladder].
    Cardozo L; Lisec M; Milard R; Van Vierssen Trip O; Kuzmin I; Drogendijk TE; Huang AM
    Akush Ginekol (Sofiia); 2007; 46(5):55-7. PubMed ID: 17974184
    [No Abstract]   [Full Text] [Related]  

  • 19. Electroacupuncture versus solifenacin succinate for female overactive bladder: study protocol for a multicentre, randomised, controlled, double-dummy, non-inferiority trial.
    Chen B; Yin P; Li J; Hou W; Fan Q; Huai Y; Liu L; Hu J; Chow ST; Li X; Ming S; Chen YL
    BMJ Open; 2024 Sep; 14(9):e076374. PubMed ID: 39266323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Redefining response in overactive bladder syndrome.
    Payne CK; Kelleher C
    BJU Int; 2007 Jan; 99(1):101-6. PubMed ID: 17227496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.